Lactobacillus rhamnosus Probiotics for Diarrhea Prevention

Combination live biotherapeutic treatments for restoring microbiome balance to treat diseases like infant diarrhea and vaginal infections. The treatments involve administering a specific blend of bacteria strains, Bifidobacterium and Vertebrate-Associated Lactobacillaceae, that inhibit pathogen growth and immune responses. The bacteria strains are chosen to have synergistic effects when cultured together. This combination therapy aims to improve efficacy and reduce dosage compared to single strain probiotics.

Source

The genus Lactobacillus is a heterogeneous group of lactic acid bacteria (LAB) with important implications in biotechnology. It is a predominant microorganism in the world of gastrointestinal health, but various other uses are being explored. They have long been considered in the generally recognized as safe (GRAS) category by the Food and Drug Authority (FDA). They have been extensively used in fermentation and there is growing interest regarding their use in gut health, vaccine production, and biomedical innovation. This chapter highlights the application of lactobacilli in healthcare.

Source

Abstract Antibiotic associated diarrhea frequently complicates treatment of infections. A recent randomized, double-blind, placebo-controlled trial tested a proprietary probiotic mixture and found it reduced the incidence of AAD by 16%. This is encouraging for patients, but future progress on probiotics for AAD and other conditions depends on transparency around strain selection, probiotic design guided by preclinical mechanistic studies, and rigorously conducted human studies.

Source

Abstract Diarrheal diseases remain the leading cause of high mortality among the infants, particularly in the developing countries; Probiotic intervention for diarrhea has been an ongoing novel approach to diarrheal prevention and treatment. This study aims to characterize immunogenic and probiotic properties of lactic acid bacteria (LAB) isolated from human breast milk and neonates faeces. The LAB isolates from 16 mothers breast milk and 13 infants faeces were screened and identified by 16 S rRNA gene partial sequencing. Their antimicrobial activities against 5 strains of diarrheagenic Escherichia coli were tested. Organic acids production was quantified by HPLC, and antibiotic resistance pattern were determined by VITEK . Autoaggregation, co-aggregation and hydrophobicity properties were assessed by UV spectrophotometry and immunomodulatory effect was determined in mouse model. Ninety-three LAB of five genera were identified. The most abundant species was Lactiplantibacillus plantarum with inhibition zones ranged from 8.0 to 25.0 1 mm. Lacticaseibacillus rhamnosus A012 had 7... Read More

Source

A probiotic protein complex vitamin comprising immune protein activation factor, complex vitamins, maca powder, panax notoginseng powder, dextrin, and corn starch, with a simultaneous fermentation process of multiple strains. The vitamin formulation is designed to enhance immune function, metabolic pathways, and overall physical fitness, while also promoting gastrointestinal health and preventing diarrhea.

Source

The gut microbiota is the central regulator of human metabolism, it is considered a superorganism, it fulfills functions related to homeostasis and the maintenance of systemic health, contributing to immunity and epithelial integrity, any alteration is related to non-compliance or interruption of some of its functions, for this reason in search of balance, prevention and treatment measures have been implemented, one of them is the use of probiotics, which has been proven to bring beneficial actions towards the health of the host. , such as lactobacillus and bifidobacteria, here we will review the association between gut microbiota, probiotics and the use of probiotics like a treatment of prevention for pathologies of gut microbiota.

Source

A novel use of Lactobacillus paracasei subsp. paracasei K56 for enhancing intestinal immunity and resistance to bacterial infection. The strain significantly reduces pathogenic bacterial adhesion to intestinal epithelial cells, improves barrier function, and activates intestinal immunity. It can be used in food, pharmaceutical, or feed products to prevent diarrhea and combat bacterial infections.

Source

Conventional dairy probiotics products that include yogurts/curds and cheese are considered the chief source of probiotic microbiome. Several health benefits have been attributed to the ingestion of probiotic microbiome. They were supposed to improve immunity and increase resistance to infection and improve general well-being. They aid in the digestion of lactose, which results in the reduction in intestinal bloating, flatulence, and discomfort. It has also been suggested that they offer protection against Clostridium botulinum spores and associated toxins (a feasible reason for abrupt sudden infant death syndrome or infant death syndrome). To prevent and treat diarrheal disorder, the most acknowledged therapeutic submission is probiotics administration. The diarrhea disorders include rota virus-induced diarrhea in toddlers and old-age people. They prevent infection and traveler's diarrhea and protect against some kinds of cancer. Decrease in blood cholesterol levels and reduction in incidence of cardiovascular disease have also been attributed to probiotics. Probiotics specifically ... Read More

Source

Background. One of the important links in the pathogenesis of irritable bowel syndrome (IBS) is a change in the composition of the microbiota, and therefore, the use of probiotics in complex therapy can be considered as a pathogenetic treatment of this functional disease. Aim. To study the effectiveness of probiotic use on the composition of the intestinal microbiota and the dynamics of symptoms in patients with IBS with predominance of diarrhea (IBS-D) or constipation (IBS-C). Materials and methods. 10 patients with IBS-D and 7 patients with IBS-C who took a probiotic for 28 days, which included: Lactobacillus acidophilus 1.25109 CFU, Bifidobacterium lactis 1.25109 CFU, Lactobacillus paracasei 1.25109 CFU, Lactobacillus rhamnosus 1.25109 CFU. The dynamics of symptoms was assessed using the Gastrointestinal Symptom Rating Scale, and the composition of the microbiota before and after taking the probiotic was analyzed by sequencing 16S pRNA of stool samples. Results. In both groups, we found a statistically significant decrease in the level of Proteobacteria and an increase i... Read More

Source

Background: Regarding the appropriate effect of probiotics in treating acute diarrhea and the high prevalence of non-bacterial acute diarrhea among children in the population. Objectives: The present study evaluates the effect of synbiotic drops in children with acute diarrhea, including the number of hospitalization days, daily excreted diarrhea volume, duration of diarrhea, and reduction in the number of excretions between the case and control groups. Methods: This was a prospective double-blinded and randomized-controlled clinical trial on children aged 6 - 24 months with non-bloody acute diarrhea were included. The reason for hospitalization was diarrhea. In the case group, the patients consume PediLact (Zisttakhmir, Tehran, Iran) drop (Lactobacillus rhamnosus, Lactobacillus reuteri, and bifidobacterium infantis) 109 CFU and fructooligosaccharides. PediLact drop was used with milk or lukewarm food for five days along with other routine hospital cares. The number of hospitalization days, the daily excreted diarrhea, diarrhea duration, and decreasing numbers of excretion in patient... Read More

Source

As our understanding of the intricate interaction between gut bacteria and human health continues to expand, so too has interest in the ability of probiotics to manage gut microbiota and confer multiple health benefits to the host. The mini literature review focuses on the expanding potential of the use of probiotics in GI health, with a focus on probiotics' potential therapeutic advantages in a variety of gastrointestinal (GI) illnesses. Probiotics play a significant role in managing diarrhea and symptoms of irritable bowel syndrome with diarrhea (IBS-D) by modulating gut microbial communities. Specific probiotic strains have been found to reduce the abundance of harmful bacteria, regulate inflammatory markers like interleukin 6, and improve GI symptoms such as abdominal discomfort and stool consistency. Additionally, probiotic blends have shown potential for preventing GI infections and alleviating GI pain in IBS-D patients. Studies have demonstrated that certain multi-strain probiotics, including Bifidobacterium and Lactobacillus species, can significantly increase the frequency o... Read More

Source

Diarrhea is an atypical state of the digestive system characterized by a soft or watery texture in bowel movements. Antibiotic-related diarrhea is common in the elderly due to extensive antibiotic use. Probiotics are vital microorganisms that support the intestinal flora and reduce bacterial colonization in the intestinal wall. This study aimed to assess the effectiveness, type, and dose of probiotics for diarrhea in the elderly. A systematic review with meta-analysis was conducted using PubMed, ScienceDirect, and Google Scholar. Seven records with a total of 2,087 participants were included. A quantitative analysis was carried out using Review Manager version 5 software. A meta-analysis was conducted to assess the frequency of diarrhea. The results showed that using probiotics significantly reduced the risk of antibiotic-related diarrhea 0.53 times compared to the placebo administration (OR 0.53; CI 95% 0.29 to 0.98; I2 = 70%). The type of probiotics frequently given was the genera of Lactobacillus, Bifidobacterium, and Streptococcus, with consumption durations varying from 3 days t... Read More

Source

Lactic acid bacteria produce various beneficial metabolites, including antimicrobial agents. Owing to the fast-rising antibiotic resistance among pathogenic microbes, scientists are exploring antimicrobials beyond antibiotics. In this study, we examined four Lactobacillus strains, namely L. plantarum 42, L. brevis 205, L. rhamnosus 239, and L. delbrueckii 263, isolated from healthy human microbiota, to evaluate their antibacterial and antifungal activity.

Source

Abstract: This study explores the potential of using probiotic lactic acid bacteria (LAB) that produce bacteriocins as a novel approach to controlling gut microbiota dysbiosis. Gut dysbiosis, characterized by an imbalance in the composition of the gut microbiota, is implicated in various health disorders. Probiotic LAB have gained attention for their ability to promote a balanced gut microbiota. Bacteriocin-producing LAB offer an added advantage by inhibiting pathogenic bacteria and promoting the growth of beneficial microbes. This review summarizes the current knowledge on the mechanisms of probiotic LAB and their bacteriocins in modulating gut microbiota composition. Additionally, key clinical studies and potential applications of bacteriocin-producing LAB in mitigating gut dysbiosis are discussed.

Source

Background: Antibiotic-associated diarrhea is a condition reported in 535% of patients treated with antibiotics, especially in older patients with comorbidities. In most cases, antibiotic-associated diarrhea is not associated with serious complications, but it can prolong hospitalization and provoke Clostridium difficile infection. An important role in the prevention of antibiotic-associated diarrhea is carried out by some probiotic strains such as Lactobacillus GG or the yeast Saccharomyces boulardii that showed good efficacy and a significant reduction in antibiotic-associated diarrhea. Similarly, the Limosilactobacillus reuteri DSM 17938 showed significant benefits in acute diarrhea, reducing its duration and abdominal pain. Aim: The aim of this study was to test the efficacy of a mix of two probiotic strains (Limosilactobacillus reuteri LMG P-27481 and Lacticaseibacillus rhamnosus GG ATCC 53103; Reuterin GG, NOOS, Italy), in association with antibiotics (compared to antibiotics used alone), in reducing antibiotic-associated diarrhea, clostridium difficile infection, and other g... Read More

Source

As different probiotic supplements become increasingly seen in the market, questions regarding their use for gut health from patients rises as well. Because these supplements do not require FDA approval, their safety and efficacy is often unknown and limited research available poses an even greater challenge for healthcare providers when prompted with questions regarding their use. This article summarizes evidence-based recommendations provided by the American Gastroenterological Association (AGA) and the World Gastroenterology Organization (WGO). Of the conditions discussed, supportive evidence on the use of probiotics is mostly seen in the prevention of C. diff associated diarrhea, prevention of antibiotic associated diarrhea and treatment of IBS. Of the millions of different strains available, the recurring genus seen across multiple disease states is Lactobacillus. It is most known that probiotics serve as a source of good bacteria, but these supplements may pose a threat in certain patient populations and require careful consideration between patients and providers before star... Read More

Source

Lacticaseibacillus rhamnosus GG (LGG) is the world's most consumed probiotic but its mechanism of action on intestinal permeability and differentiation along with its interactions with an essential source of signaling metabolites, dietary tryptophan (trp), are unclear.

Source

Diarrhea is a common unfavorable consequence of antibiotics. Probiotic yogurt is equally effective as probiotic capsules, so it may provide a simple and cost-effective means of preventing antibiotic-associated diarrhea (AAD). The study aimed to evaluate the effect of probiotic yogurt on AAD among pediatric patients.

Source

Infant feces and breast milk are sources of lactic acid bacteria with interesting functional and technological properties. Therefore, we focused on the isolation and characterization of new potential probiotic strains from infant feces and breast milk. Nine strains were identified based on 16S rRNA sequences of Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Lactobacillus gasseri. Subsequently, these isolates were evaluated for their safety (antibiotic resistance, hemolytic, and enzymatic activity) and functional properties (gastrointestinal condition tolerance, hydrophobicity, auto-aggregation, adhesion to Caco-2/HT-29 cell lines, antimicrobial and antioxidant properties, and the production of exopolysaccharides). All the isolates were non-hemolytic and resistant to streptomycin, kanamycin, and vancomycin. They also demonstrated antimicrobial activity against five selected pathogens (Staphylococcus aureus, Bacillus cereus, Escherichia coli, Salmonella sp., and Enterococcus faecalis) and the production of exopolysaccharides. Isolates Lacticaseibacillus rhamnosus S1F an... Read More

Source

Antibiotic-associated diarrhea (AAD) refers to diarrhea caused by gut microbiota disorders after the use of antibiotics, which seriously threatens the health of humans and animals. Therefore, it is necessary to find an effective therapy to treat AAD. This research aimed to explore the effects of Lactobacillus plantarum H-6 (L. plantarum H-6) and Weissella viridescens J-1 (W. viridescens J-1) on alleviating antibiotic-associated diarrhea induced by lincomycin hydrochloride (LH) in mice. The results show that L. plantarum H-6 could significantly reduce the expression of pro-inflammatory factors such as IL-1 and IL-6 in colon tissue. At the same time, L. plantarum H-6 significantly increased the abundance of Lactobacillus and Akkermansia, decreased the abundance of Bacteroides, and increased the contents of L-tryptophan, LysoPC (20:4 (8Z, 11Z, 14Z, 17Z)), reduced riboflavin, threoninylmethionine, and N-palmitoyl in serum. However, W. viridescens J-1 had little effect on the treatment of AAD. It can be concluded that L. plantarum H-6 can regulate mices colonic microbial composition, i... Read More

Source